Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Seminars in Immunopathology
Erschienen in: Seminars in Immunopathology 5/2014

01.09.2014 | Review

Use of animal models in elucidating disease pathogenesis in IBD

verfasst von: Puja Vora Khanna, David Quan Shih, Talin Haritunians, Dermot Patrick McGovern, Stephan Targan

Erschienen in: Seminars in Immunopathology | Ausgabe 5/2014

Einloggen, um Zugang zu erhalten

Abstract

Inflammatory bowel diseases (IBD) are a collection of diseases characterized by chronic gastrointestinal inflammation resulting from an exuberant immune response to commensal flora in genetically susceptible individuals. Rapid advances in the field of genomics have resulted in the identification of at least 163 loci that contribute susceptibility to both Crohn’s disease (CD) and ulcerative colitis (UC). Similar to other complex diseases, however, the “curse of missing heritability” remains a significant concern in understanding the mechanisms underlying IBD. While genetic discoveries, to date, only account for 7–14 % of disease variance for IBD, studies have increasingly demonstrated a role for environmental factors in disease pathogenesis. Furthermore, the use of animal models of IBD has led to a greater understanding of disease pathogenesis implicating various aspects of the innate immune response including the bacterial, fungal, and viral microbiome and adaptive immune response such as the interleukin (IL)-23/IL-17 pathway.
Literatur
1.
Jostins L, Ripke S, Weersma RK et al (2012) Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491:119–24PubMedCrossRefPubMedCentral
2.
Dethlefsen L, McFall-Ngai M, Relman DA (2007) An ecological and evolutionary perspective on human-microbe mutualism and disease. Nature 449:811–8PubMedCrossRef
3.
4.
5.
Greenblum S, Turnbaugh PJ, Borenstein E (2012) Metagenomic systems biology of the human gut microbiome reveals topological shifts associated with obesity and inflammatory bowel disease. Proc Natl Acad Sci USA 109:594–9PubMedCrossRefPubMedCentral
6.
Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R (2012) Diversity, stability and resilience of the human gut microbiota. Nature 489:220–30PubMedCrossRefPubMedCentral
7.
8.
Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR (2007) Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA 104:13780–5PubMedCrossRefPubMedCentral
9.
Tong M, Li X, Wegener Parfrey L et al (2013) A modular organization of the human intestinal mucosal microbiota and its association with inflammatory bowel disease. PLoS One 8:e80702PubMedCrossRefPubMedCentral
10.
Gevers D, Kugathasan S, Denson LA et al (2014) The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host Microbe 15:382–92PubMedCrossRef
11.
Ogura Y, Bonen DK, Inohara N et al (2001) A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature 411:603–6PubMedCrossRef
12.
Hugot JP, Chamaillard M, Zouali H et al (2001) Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature 411:599–603PubMedCrossRef
13.
Hugot JP, Laurent-Puig P, Gower-Rousseau C et al (1996) Mapping of a susceptibility locus for Crohn’s disease on chromosome 16. Nature 379:821–3PubMedCrossRef
14.
Franke A, McGovern DP, Barrett JC et al (2010) Genome-wide meta-analysis increases to 71 the number of confirmed Crohn’s disease susceptibility loci. Nat Genet 42:1118–25PubMedCrossRefPubMedCentral
15.
Barrett JC, Hansoul S, Nicolae DL et al (2008) Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease. Nat Genet 40:955–62PubMedCrossRefPubMedCentral
16.
Rivas MA, Beaudoin M, Gardet A et al (2011) Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease. Nat Genet 43:1066–73PubMedCrossRefPubMedCentral
17.
Kufer TA, Banks DJ, Philpott DJ (2006) Innate immune sensing of microbes by Nod proteins. Ann N Y Acad Sci 1072:19–27PubMedCrossRef
18.
Travassos LH, Carneiro LA, Ramjeet M et al (2010) Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nat Immunol 11:55–62PubMedCrossRef
19.
Cooney R, Baker J, Brain O et al (2010) NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat Med 16:90–7PubMedCrossRef
20.
Petnicki-Ocwieja T, Hrncir T, Liu YJ et al (2009) Nod2 is required for the regulation of commensal microbiota in the intestine. Proc Natl Acad Sci USA 106:15813–8PubMedCrossRefPubMedCentral
21.
Frank DN, Robertson CE, Hamm CM et al (2011) Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases. Inflamm Bowel Dis 17:179–84PubMedCrossRef
22.
Li E, Hamm CM, Gulati AS et al (2012) Inflammatory bowel diseases phenotype, C. difficile and NOD2 genotype are associated with shifts in human ileum associated microbial composition. PLoS One 7:e26284PubMedCrossRefPubMedCentral
23.
Rodemann JF, Dubberke ER, Reske KA, da Seo H, Stone CD (2007) Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol: Off Clin Pract J Am Gastroenterol Assoc 5:339–44CrossRef
24.
Strober W, Asano N, Fuss I, Kitani A, Watanabe T (2014) Cellular and molecular mechanisms underlying NOD2 risk-associated polymorphisms in Crohn’s disease. Immunol Rev 260:249–60PubMedCrossRef
25.
Rehman A, Sina C, Gavrilova O et al (2011) Nod2 is essential for temporal development of intestinal microbial communities. Gut 60:1354–62PubMedCrossRef
26.
Natividad JM, Petit V, Huang X et al (2012) Commensal and probiotic bacteria influence intestinal barrier function and susceptibility to colitis in Nod1−/−; Nod2−/− mice. Inflamm Bowel Dis 18:1434–46PubMedCrossRef
27.
Kelly RJ, Rouquier S, Giorgi D, Lennon GG, Lowe JB (1995) Sequence and expression of a candidate for the human Secretor blood group alpha(1,2)fucosyltransferase gene (FUT2). Homozygosity for an enzyme-inactivating nonsense mutation commonly correlates with the non-secretor phenotype. J Biol Chem 270:4640–9PubMedCrossRef
28.
Ferrer-Admetlla A, Sikora M, Laayouni H et al (2009) A natural history of FUT2 polymorphism in humans. Mol Biol Evol 26:1993–2003PubMedCrossRef
29.
McGovern DP, Jones MR, Taylor KD et al (2010) Fucosyltransferase 2 (FUT2) non-secretor status is associated with Crohn’s disease. Hum Mol Genet 19:3468–3476PubMedCrossRefPubMedCentral
30.
Rausch P, Rehman A, Kunzel S et al (2011) Colonic mucosa-associated microbiota is influenced by an interaction of Crohn disease and FUT2 (Secretor) genotype. Proc Natl Acad Sci USA 108:19030–5PubMedCrossRefPubMedCentral
31.
Tong M, McHardy I, Ruegger P et al (2014) Reprograming of gut microbiome energy metabolism by the FUT2 Crohn’s disease risk polymorphism. ISME J 6:610–618
32.
Wacklin P, Makivuokko H, Alakulppi N et al (2011) Secretor genotype (FUT2 gene) is strongly associated with the composition of Bifidobacteria in the human intestine. PLoS One 6:e20113PubMedCrossRefPubMedCentral
33.
Morgan XC, Tickle TL, Sokol H et al (2012) Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol 13:R79PubMedCrossRefPubMedCentral
34.
Hampe J, Franke A, Rosenstiel P et al (2007) A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn’s disease in ATG16L1. Nat Genet 39:207–11PubMedCrossRef
35.
Rioux JD, Xavier RJ, Taylor KD et al (2007) Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat Genet 39:596–604PubMedCrossRefPubMedCentral
36.
Parkes M, Barrett JC, Prescott NJ et al (2007) Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn’s disease susceptibility. Nat Genet 39:830–2PubMedCrossRefPubMedCentral
37.
McCarroll SA, Huett A, Kuballa P et al (2008) Deletion polymorphism upstream of IRGM associated with altered IRGM expression and Crohn’s disease. Nat Genet 40:1107–12PubMedCrossRefPubMedCentral
38.
Cadwell K, Liu JY, Brown SL et al (2008) A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells. Nature 456:259–63PubMedCrossRefPubMedCentral
39.
Cadwell K, Patel KK, Maloney NS et al (2010) Virus-plus-susceptibility gene interaction determines Crohn’s disease gene Atg16L1 phenotypes in intestine. Cell 141:1135–45PubMedCrossRefPubMedCentral
40.
Lawlor G, Moss AC (2010) Cytomegalovirus in inflammatory bowel disease: pathogen or innocent bystander? Inflamm Bowel Dis 16:1620–7PubMedCrossRef
41.
42.
Sankaran-Walters S, Ransibrahmanakul K, Grishina I et al (2011) Epstein-Barr virus replication linked to B cell proliferation in inflamed areas of colonic mucosa of patients with inflammatory bowel disease. J Clin Virol: Off Publ Pan Am Soc Clin Virol 50:31–6CrossRef
43.
Pironi L, Bonvicini F, Gionchetti P et al (2009) Parvovirus b19 infection localized in the intestinal mucosa and associated with severe inflammatory bowel disease. J Clin Microbiol 47:1591–5PubMedCrossRefPubMedCentral
44.
Underhill DM, Iliev ID (2014) The mycobiota: interactions between commensal fungi and the host immune system. Nat Rev Immunol 14:405–16PubMedCrossRef
45.
Ott SJ, Kuhbacher T, Musfeldt M et al (2008) Fungi and inflammatory bowel diseases: alterations of composition and diversity. Scand J Gastroenterol 43:831–41PubMedCrossRef
46.
47.
Brown GD (2006) Dectin-1: a signalling non-TLR pattern-recognition receptor. Nat Rev Immunol 6:33–43PubMedCrossRef
48.
Taylor PR, Tsoni SV, Willment JA et al (2007) Dectin-1 is required for beta-glucan recognition and control of fungal infection. Nat Immunol 8:31–8PubMedCrossRefPubMedCentral
49.
Gross O, Gewies A, Finger K et al (2006) Card9 controls a non-TLR signalling pathway for innate anti-fungal immunity. Nature 442:651–6PubMedCrossRef
50.
51.
Glocker EO, Hennigs A, Nabavi M et al (2009) A homozygous CARD9 mutation in a family with susceptibility to fungal infections. N Engl J Med 361:1727–35PubMedCrossRefPubMedCentral
52.
Sutton CL, Yang H, Li Z, Rotter JI, Targan SR, Braun J (2000) Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in affected and unaffected relatives of patients with Crohn’s disease. Gut 46:58–63PubMedCrossRefPubMedCentral
53.
Seow CH, Stempak JM, Xu W et al (2009) Novel anti-glycan antibodies related to inflammatory bowel disease diagnosis and phenotype. Am J Gastroenterol 104:1426–34PubMedCrossRef
54.
Walker LJ, Aldhous MC, Drummond HE et al (2004) Anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn’s disease are associated with disease severity but not NOD2/CARD15 mutations. Clin Exp Immunol 135:490–6PubMedCrossRefPubMedCentral
55.
McGovern DP, Gardet A, Torkvist L et al (2010) Genome-wide association identifies multiple ulcerative colitis susceptibility loci. Nat Genet 42:332–7PubMedCrossRefPubMedCentral
56.
Zhernakova A, Festen EM, Franke L et al (2008) Genetic analysis of innate immunity in Crohn’s disease and ulcerative colitis identifies two susceptibility loci harboring CARD9 and IL18RAP. Am J Hum Genet 82:1202–10PubMedCrossRefPubMedCentral
57.
Iliev ID, Funari VA, Taylor KD et al (2012) Interactions between commensal fungi and the C-type lectin receptor Dectin-1 influence colitis. Science 336:1314–7PubMedCrossRefPubMedCentral
58.
Oppmann B, Lesley R, Blom B et al (2000) Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13:715–25PubMedCrossRef
59.
Hunter CA (2005) New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat Rev Immunol 5:521–31PubMedCrossRef
60.
Dong C (2008) TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol 8:337–48PubMedCrossRef
61.
Mannon PJ, Fuss IJ, Mayer L et al (2004) Anti-interleukin-12 antibody for active Crohn’s disease. N Engl J Med 351:2069–79PubMedCrossRef
62.
Buonocore S, Ahern PP, Uhlig HH et al (2010) Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology. Nature 464:1371–5PubMedCrossRefPubMedCentral
63.
Sandborn WJ, Feagan BG, Fedorak RN et al (2008) A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s disease. Gastroenterology 135:1130–41PubMedCrossRef
64.
Papp KA, Langley RG, Lebwohl M et al (2008) Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371:1675–84PubMedCrossRef
65.
Yen D, Cheung J, Scheerens H et al (2006) IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 116:1310–6PubMedCrossRefPubMedCentral
66.
Ahern PP, Schiering C, Buonocore S et al (2010) Interleukin-23 drives intestinal inflammation through direct activity on T cells. Immunity 33:279–88PubMedCrossRefPubMedCentral
67.
Sujino T, Kanai T, Ono Y et al (2011) Regulatory T cells suppress development of colitis, blocking differentiation of T-helper 17 into alternative T-helper 1 cells. Gastroenterology 141:1014–23PubMedCrossRef
68.
69.
Salehi S, Bankoti R, Benevides L et al (2012) B lymphocyte-induced maturation protein-1 contributes to intestinal mucosa homeostasis by limiting the number of IL-17-producing CD4+ T cells. J Immunol 189:5682–93PubMedCrossRefPubMedCentral
70.
Kolls JK, Linden A (2004) Interleukin-17 family members and inflammation. Immunity 21:467–76PubMedCrossRef
71.
Zhang Z, Zheng M, Bindas J, Schwarzenberger P, Kolls JK (2006) Critical role of IL-17 receptor signaling in acute TNBS-induced colitis. Inflamm Bowel Dis 12:382–8PubMedCrossRef
72.
Elson CO, Cong Y, Weaver CT et al (2007) Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology 132:2359–70PubMedCrossRef
73.
Kullberg MC, Jankovic D, Feng CG et al (2006) IL-23 plays a key role in Helicobacter hepaticus-induced T cell-dependent colitis. J Exp Med 203:2485–94PubMedCrossRefPubMedCentral
74.
Becker C, Dornhoff H, Neufert C et al (2006) Cutting edge: IL-23 cross-regulates IL-12 production in T cell-dependent experimental colitis. J Immunol 177:2760–4PubMedCrossRef
75.
O’Connor W Jr, Kamanaka M, Booth CJ et al (2009) A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat Immunol 10:603–9PubMedCrossRefPubMedCentral
76.
Ogawa A, Andoh A, Araki Y, Bamba T, Fujiyama Y (2004) Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice. Clin Immunol 110:55–62PubMedCrossRef
77.
78.
Bettelli E, Carrier Y, Gao W et al (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441:235–8PubMedCrossRef
79.
Hovhannisyan Z, Treatman J, Littman DR, Mayer L (2011) Characterization of interleukin-17-producing regulatory T cells in inflamed intestinal mucosa from patients with inflammatory bowel diseases. Gastroenterology 140:957–65PubMedCrossRefPubMedCentral
80.
Sakuraba A, Sato T, Kamada N, Kitazume M, Sugita A, Hibi T (2009) Th1/Th17 immune response is induced by mesenteric lymph node dendritic cells in Crohn’s disease. Gastroenterology 137:1736–45PubMedCrossRef
81.
82.
83.
Holtta V, Klemetti P, Sipponen T et al (2008) IL-23/IL-17 immunity as a hallmark of Crohn’s disease. Inflamm Bowel Dis 14:1175–84PubMedCrossRef
84.
Seiderer J, Elben I, Diegelmann J et al (2008) Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): upregulated colonic IL-17F expression in active Crohn’s disease and analysis of the IL17F p.His161Arg polymorphism in IBD. Inflamm Bowel Dis 14:437–45PubMedCrossRef
85.
86.
Taraban VY, Slebioda TJ, Willoughby JE et al (2011) Sustained TL1A expression modulates effector and regulatory T-cell responses and drives intestinal goblet cell hyperplasia. Mucosal Immunol 4:186–96PubMedCrossRefPubMedCentral
87.
Prehn JL, Thomas LS, Landers CJ, Yu QT, Michelsen KS, Targan SR (2007) The T cell costimulator TL1A is induced by FcgammaR signaling in human monocytes and dendritic cells. J Immunol 178:4033–8PubMedCrossRef
88.
Shih DQ, Kwan LY, Chavez V et al (2009) Microbial induction of inflammatory bowel disease associated gene TL1A (TNFSF15) in antigen presenting cells. Eur J Immunol 39:3239–50PubMedCrossRefPubMedCentral
89.
Meylan F, Davidson TS, Kahle E et al (2008) The TNF-family receptor DR3 is essential for diverse T cell-mediated inflammatory diseases. Immunity 29:79–89PubMedCrossRefPubMedCentral
90.
Kamada N, Hisamatsu T, Honda H et al (2010) TL1A produced by lamina propria macrophages induces Th1 and Th17 immune responses in cooperation with IL-23 in patients with Crohn’s disease. Inflamm Bowel Dis 16:568–75PubMedCrossRef
91.
Endo K, Kinouchi Y, Kakuta Y, Ueki N, Takahashi S, Shimosegawa T (2009) Involvement of NF-kappa B pathway in TL1A gene expression induced by lipopolysaccharide. Cytokine 2009
92.
Takedatsu H, Michelsen KS, Wei B et al (2008) TL1A (TNFSF15) regulates the development of chronic colitis by modulating both T-helper 1 and T-helper 17 activation. Gastroenterology 135:552–67PubMedCrossRefPubMedCentral
93.
94.
Jones GW, Stumhofer JS, Foster T et al (2011) Naive and activated T cells display differential responsiveness to TL1A that affects Th17 generation, maintenance, and proliferation. FASEB J: Off Publ Fed Am Soc Exp Biol 25:409–19CrossRef
95.
Bettelli E, Korn T, Oukka M, Kuchroo VK (2008) Induction and effector functions of T(H)17 cells. Nature 453:1051–7PubMedCrossRef
96.
Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B (2006) TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24:179–89PubMedCrossRef
97.
Mangan PR, Harrington LE, O’Quinn DB et al (2006) Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 441:231–4PubMedCrossRef
98.
Leonardi C, Matheson R, Zachariae C et al (2012) Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 366:1190–9PubMedCrossRef
99.
Hueber W, Sands BE, Lewitzky S et al (2012) Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 61:1693–700PubMedCrossRef
100.
Wallace KL ZL, Kanazawa Y, Zhang H, Ichikawa R, Chen J, Sidhu M, Zhang X, Pothoulakis C, Koon HW, Targan S, Shih DQ (2014) Tl1a modulates the differential effect of IL-17 blockade on mucosal inflammation. Gastroenterology 146:S-133CrossRef
101.
Michelsen KS, Thomas LS, Taylor KD et al (2009) IBD-associated TL1A gene (TNFSF15) haplotypes determine increased expression of TL1A protein. PLoS One 4:e4719PubMedCrossRefPubMedCentral
Metadaten
Titel
Use of animal models in elucidating disease pathogenesis in IBD
verfasst von
Puja Vora Khanna
David Quan Shih
Talin Haritunians
Dermot Patrick McGovern
Stephan Targan
Publikationsdatum
01.09.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Seminars in Immunopathology / Ausgabe 5/2014
Print ISSN: 1863-2297
Elektronische ISSN: 1863-2300
DOI
https://doi.org/10.1007/s00281-014-0444-6

Weitere Artikel der Ausgabe 5/2014

Seminars in Immunopathology 5/2014 Zur Ausgabe

Review

Immune sensing of nucleic acids in inflammatory skin diseases

Review

Mechanisms of tissue damage in arthritis

Review

Mechanisms of tissue injury in autoimmune liver diseases

Review

Beyond canonical inflammasomes: emerging pathways in IL-1-mediated autoinflammatory disease

Review

Insulitis in human type 1 diabetes: a comparison between patients and animal models

Editorial

Introduction: mechanisms of tissue injury in autoimmune diseases

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise